Aromasin (generic name exemestane) is a prescription medication classified as an aromatase inhibitor and is used as part of oncology support for hormone-responsive breast cancer. It is supplied as a 25 mg oral pill. In Hong Kong, the drug is regulated by the Department of Health under the Pharmacy and Poisons Ordinance and is available only with a medical prescription.
Exemestane belongs to the steroidal aromatase inhibitor class. Aromatase is an enzyme that converts androgens (such as testosterone) into estrogens. By binding irreversibly to the aromatase enzyme, exemestane reduces estrogen production throughout the body. Lower estrogen levels help to slow the growth of estrogen-dependent breast cancer cells.
Aromasin is approved for the adjuvant treatment of post-menopausal women with hormone-receptor-positive early breast cancer. It may also be used in the metastatic setting when disease progression occurs after prior endocrine therapy. The indication is consistent with approvals from the U.S. FDA, the European EMA, and the Hong Kong Department of Health.
Exemestane has been studied off-label for conditions such as gynecomastia prevention in men receiving androgen deprivation therapy and male breast cancer. These uses are not approved by regulatory agencies in Hong Kong.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
These effects are typically mild to moderate and often improve with continued therapy or supportive measures such as lifestyle adjustments and over-the-counter analgesics.
If you are taking other prescription drugs, supplements, or herbal products, discuss potential interactions with your pharmacist or oncologist.
This article provides educational information about Aromasin (exemestane) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Severe joint pain may be a side effect of estrogen suppression. Discuss the symptom with your oncologist; they may recommend analgesics, physical therapy, or a temporary dose adjustment.
Aromatase inhibitors can modestly increase LDL cholesterol and decrease HDL cholesterol in some patients. Periodic lipid panel testing is advisable, and dietary modifications may be recommended.
Yes, calcium (with vitamin D) is often prescribed to counteract bone loss associated with aromatase inhibition. Follow the dosage guidance provided by your healthcare team.
The duration of adjuvant therapy varies; many protocols prescribe 5 years of continuous aromatase inhibition, but your oncologist will tailor the schedule based on individual risk factors.
Exemestane suppresses estrogen production, so it counteracts the effects of HRT. Concurrent use is generally avoided unless a specialist explicitly recommends a combined approach.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of any country-specific import restrictions for prescription drugs.
Aromasin 25 mg tablets are typically round, white, and bear the imprint “EXE 25”. Verify the imprint and packaging against the pharmacist’s label.
No specific foods must be avoided, but a balanced diet rich in calcium and vitamin D supports bone health. Excessive grapefruit juice can affect drug metabolism and should be limited.
Both suppress estrogen, but exemestane is a steroidal (irreversible) inhibitor, whereas letrozole is non-steroidal (reversible). Clinical choice depends on patient tolerance, prior therapy, and physician preference.
Yes. Supplements such as St. John’s wort can induce liver enzymes and lower exemestane levels. Provide a complete list of all products you use to your pharmacist or oncologist.
